Bristol Myers Squibb’s Camzyos gets NICE recommendation
Therapy is used among adult patients with symptomatic obstructive hypertrophic cardiomyopathy
Read Moreby John Pinching | Sep 6, 2023 | News | 0
Therapy is used among adult patients with symptomatic obstructive hypertrophic cardiomyopathy
Read Moreby John Pinching | Jul 3, 2023 | News | 0
The therapy becomes an option for moderate-to-severe plaque psoriasis in certain adults
Read Moreby Lucy Parsons | Aug 4, 2021 | News | 0
Phase III trials did not demonstrate sufficient clinical benefit.
Read Moreby Lucy Parsons | May 24, 2021 | News | 0
At six and a half years 49% of patients treated with combination therapy remained alive
Read Moreby Selina McKee | Apr 9, 2021 | News | 0
The combination is not considered to be a cost-effective use of NHS resources in this setting
Read Moreby Selina McKee | Sep 18, 2020 | News | 0
The drug has been approved for routine NHS commissioning for squamous or non-squamous NSCLC
Read Moreby Selina McKee | Sep 2, 2020 | News | 0
The oral therapy can be used as continued treatment for adults in first remission with acute myeloid leukaemia (AML)
Read Moreby Selina McKee | Jun 29, 2020 | News | 0
BMS’ Reblozyl is the first and only erythroid maturation agent approved in the EU
Read Moreby Selina McKee | May 14, 2020 | News | 0
The FDA did not request additional clinical or non-clinical data
Read Moreby Selina McKee | Apr 21, 2020 | News | 0
The combination significantly increased progression free survival when used as a first-line treatment
Read Moreby Selina McKee | Apr 9, 2020 | News | 0
The filing is based on data from the CheckMate-9LA trial, which showed a benefit in overall survival
Read Moreby Anna Smith | Feb 19, 2020 | News | 0
Bristol-Meyers Squibb said that it will continue to support the evaluation of cabiralizumab in select, ongoing investigator-sponsored trials.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479